Ozden Rabia Gurses
Insider CIK 1814883 · OCUL Chief Medical Officer · ADVM Chief Medical Officer, Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies, I | D To issuer deriv | 2025-12-09 | 2025-12-10 | 48,750 | — | $0 | 0 | SEC↗ |
| ADVM Adverum Biotechnologies, I | D To issuer deriv | 2025-12-09 | 2025-12-10 | 4,000 | — | $0 | 0 | SEC↗ |
| ADVM Adverum Biotechnologies, I | D To issuer deriv | 2025-12-09 | 2025-12-10 | 44,010 | — | $0 | 0 | SEC↗ |
| ADVM Adverum Biotechnologies, I | D To issuer deriv | 2025-12-09 | 2025-12-10 | 85,000 | — | $0 | 0 | SEC↗ |
| ADVM Adverum Biotechnologies, I | D To issuer deriv | 2025-12-09 | 2025-12-10 | 8,000 | — | $0 | 0 | SEC↗ |
| ADVM Adverum Biotechnologies, I | U Tender | 2025-12-09 | 2025-12-10 | 8,125 | — | $0 | 0 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award | 2025-12-09 | 2025-12-10 | 85,000 | — | $0 | 85,000 | SEC↗ |
| ADVM Adverum Biotechnologies, I | U Tender | 2025-12-09 | 2025-12-10 | 85,000 | — | $0 | 0 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award deriv | 2025-06-17 | 2025-06-20 | 4,000 | — | $0 | 4,000 | SEC↗ |
| ADVM Adverum Biotechnologies, I | D To issuer deriv | 2025-06-17 | 2025-06-20 | 8,000 | — | $0 | 0 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award deriv | 2025-06-17 | 2025-06-20 | 8,000 | — | $0 | 8,000 | SEC↗ |
| ADVM Adverum Biotechnologies, I | D To issuer deriv | 2025-06-17 | 2025-06-20 | 4,000 | — | $0 | 0 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award deriv | 2025-02-25 | 2025-02-27 | 48,750 | — | $0 | 48,750 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award | 2025-02-25 | 2025-02-27 | 8,125 | — | $0 | 8,125 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award deriv | 2024-08-02 | 2024-08-06 | 44,010 | — | $0 | 44,010 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award deriv | 2024-06-17 | 2024-06-20 | 85,000 | — | $0 | 85,000 | SEC↗ |
| OCUL OCULAR THERAPEUTIX, INC | S Sale | 2024-02-05 | 2024-02-06 | 6,346 | $4.86 | $30.8K | 153,054 | SEC↗ |
| OCUL OCULAR THERAPEUTIX, INC | A Award deriv | 2024-02-03 | 2024-02-06 | 200,000 | — | $0 | 200,000 | SEC↗ |
| OCUL OCULAR THERAPEUTIX, INC | A Award | 2024-02-03 | 2024-02-06 | 66,633 | — | $0 | 159,400 | SEC↗ |
| OCUL OCULAR THERAPEUTIX, INC | S Sale | 2024-01-31 | 2024-02-02 | 7,764 | $4.95 | $38.4K | 92,767 | SEC↗ |
| OCUL OCULAR THERAPEUTIX, INC | S Sale | 2023-07-07 | 2023-07-11 | 832 | $4.93 | $4.1K | 100,531 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award deriv | 2023-06-09 | 2023-06-13 | 40,000 | — | $0 | 40,000 | SEC↗ |
| OCUL OCULAR THERAPEUTIX, INC | S Sale | 2023-02-06 | 2023-02-08 | 6,416 | $4.24 | $27.2K | 101,363 | SEC↗ |
| OCUL OCULAR THERAPEUTIX, INC | A Award deriv | 2023-01-30 | 2023-02-01 | 50,000 | — | $0 | 50,000 | SEC↗ |
| OCUL OCULAR THERAPEUTIX, INC | A Award deriv | 2023-01-30 | 2023-02-01 | 166,667 | — | $0 | 166,667 | SEC↗ |
| OCUL OCULAR THERAPEUTIX, INC | A Award | 2023-01-30 | 2023-02-01 | 55,556 | — | $0 | 107,779 | SEC↗ |
| OCUL OCULAR THERAPEUTIX, INC | A Award deriv | 2022-07-14 | 2022-07-15 | 10,000 | — | $0 | 10,000 | SEC↗ |
| OCUL OCULAR THERAPEUTIX, INC | A Award deriv | 2022-07-01 | 2022-07-15 | 20,000 | — | $0 | 20,000 | SEC↗ |
| OCUL OCULAR THERAPEUTIX, INC | A Award deriv | 2022-07-01 | 2022-07-15 | 20,000 | — | $0 | 40,000 | SEC↗ |
| OCUL OCULAR THERAPEUTIX, INC | A Award | 2022-07-01 | 2022-07-15 | 6,667 | — | $0 | 52,223 | SEC↗ |
| ADVM Adverum Biotechnologies, I | A Award deriv | 2022-03-17 | 2022-03-18 | 80,000 | — | $0 | 80,000 | SEC↗ |